News

The company said that the trials compared BIL and insulin glargine in three common type 2 patients including those not previously using insulin (IMAGINE-2), those using basal insulin

The company is exhibiting the new supersequencer at the European Human Genetics Conference in Glasgow, which is being held from 6 to 9 June. The company has integrated

The deal amount will be paid by Cardinal using existing cash and new debt. The acquisition is expected to complete in the beginning of fiscal year 2016 after

In Europe, Resolor is approved for use in women, and so the new variation extends the use of this treatment to male patients. It is estimated that about

Manufactured by 3M Drug Delivery Systems, it is claimed to be the first bioequivalent alternative for GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate). It can be used for the

With the submission, the company looks to treat multiple myeloma patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an

One of the fastest growing physical therapy providers in the region, Mountain River Physical Therapy chose Clinicient’s integrated solution to increase therapist efficiency and access the advanced reporting

Produced using the patented Microcyn® Technology, The Alevicyn SG prescription product, under the supervision of a healthcare professional, is indicated to manage and relieve the burning, itching and

The trial includes an investigational therapy for patients with refractory aggressive non-Hodgkin’s lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified